Post‐progression survival is highly linked to overall survival in patients with non‐small‐cell lung cancer harboring sensitive EGFR mutations treated with first‐line epidermal growth factor receptor‐tyrosine kinase inhibitors

Post‐progression survival is highly linked to overall survival in patients with non‐small‐cell lung cancer harboring sensitive EGFR mutations treated with first‐line epidermal growth factor receptor‐tyrosine kinase inhibitors

Abstract Background In patients with epidermal growth factor receptor (EGFR)‐mutated advanced non‐small‐cell lung cancer (NSCLC), epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) treatment has shown a good response. Subsequent treatments jeopardize the ability to determine the e...

Full description

Bibliographic Details
Main Authors: Hisao Imai, Kyoichi Kaira, Keita Mori, Mie Kotake, Masumi Mitani, Naoko Kawashima, Takeshi Hisada, Koichi Minato
Format: Article
Language:English
Published: Wiley 2019-12-01
Series:Thoracic Cancer
Subjects:
Advanced non‐small‐cell lung cancer
EGFR mutations
EGFR‐TKIs
introduction
overall survival
post‐progression survival
Online Access:https://doi.org/10.1111/1759-7714.13193

Internet

https://doi.org/10.1111/1759-7714.13193

Similar Items